Liver fibrosis market to see 24% CAGR growth until 2034

Thanks to treatment advancements and better healthcare access.

The liver fibrosis market is projected to expand at a compound annual growth rate of 24% until 2034, according to a DelveInsight report.

The sector is driven by advancements in treatment options, better healthcare access, and an increasing prevalence of liver fibrosis.

“Treatments include biological and pharmacological therapies, lifestyle and dietary changes, and surgical interventions, all aimed at halting disease progression and preserving liver function,” the report said.

Meanwhile, key therapeutic targets include fibrogenic pathways, antiviral therapies, FXR agonists, and metabolic modulators to reduce inflammation and fibrosis.